De Novo and Inherited Variants in GBF1 are Associated with Axonal Neuropathy Caused by Golgi Fragmentation

Natalia Mendoza-Ferreira,1,10 Mert Karakaya,1,10 Nur Cengiz,1 Danique Beijer,2,3 Karlla W. Brigatti,4 Claudia Gonzaga-Jauregui,5 Nico Fuhrmann,1 Irmgard Hölker,1 Maximilian P. Thelen,1 Sebastian Zetsche,1 Roman Rombo,1 Erik G. Puffenberger,4 Peter De Jonghe,2,3,6 Tine Deconinck,2,3 Jonathan Baets,2,3,6 and Brunhilde Wirth1,11,*

Summary

Distal hereditary motor neuropathies (HMNs) and axonal Charcot-Marie-Tooth neuropathy (CMT2) are clinically and genetically heterogeneous diseases characterized primarily by motor neuron degeneration and distal weakness. The genetic cause for about half of the individuals affected by HMN/CMT2 remains unknown. Here, we report the identification of pathogenic variants in GBF1 (Golgi brefeldin A-resistant guanine nucleotide exchange factor 1) in four unrelated families with individuals affected by sporadic or dominant HMN/CMT2. Genomic sequencing analyses in seven affected individuals uncovered four distinct heterozygous GBF1 variants, two of which occurred de novo. Other known HMN/CMT2-implicated genes were excluded. Affected individuals show HMN/CMT2 with slowly progressive distal muscle weakness and musculoskeletal deformities. Electrophysiological studies confirmed axonal damage with chronic neurogenic changes. Three individuals had additional distal sensory loss.

Hereditary axonal neuropathies are a heterogenous group of disorders characterized by normal or moderately reduced nerve conduction velocities.1 Classically, they are classified into two subgroups depending on the affected fiber type. The distal hereditary motor neuropathies (HMNs) are characterized by pure motor neuropathy, whereas the axonal Charcot-Marie-Tooth neuropathy (CMT2) have both motor and sensory involvement.1 The cardinal phenotype of these entities is a length-dependent motor neuropathy that predominantly affects the distal foot and peroneal muscles and results in foot abnormalities or deformities and gait disturbance. Clinically, HMNs/CMT2 present with extreme heterogeneity in terms of onset, clinical course, associated neurological features (i.e., sensory or cerebellar involvement), and other co-presenting signs, including seizures, fractures, and respiratory distress, among others.2–4 This variability not only results in complex phenotypic categorizations but also in diagnostic challenges and potential misinterpretation of genetic findings.

The integration of next-generation sequencing (NGS) technologies into routine genetic diagnostics and the ensuing yield of novel disease genes has greatly expanded the number of loci associated with axonal neuropathies. Notwithstanding that, a successful genetic diagnosis is possible only in about half of the individuals with HMN/CMT2.5,6 Variants in more than 60 genes have been associated with autosomal-dominant forms of HMN or CMT2, which are phenotypically very similar (see “Muscle Gene Table” and “Inherited Neuropathy Variant Browser” in Web Resources). These genes, although functionally heterogeneous, have revealed common molecular mechanisms underlying the pathology of dominant HMNs, such as protein misfolding and aggregation,7–9 disrupted axonal transport,9,12 and mitochondria dysfunction.13–15 Over the past years, we, as well as others, have identified heterozygous variants in BICD cargo adaptor 2, also known as Bicaudal D homolog 2 (Drosophila) (BICD2 [MIM: 609797]),...
associated with dominantly inherited spinal muscular atrophy, lower extremity predominant 2A and 2B (SMA-LED2A/2B [MIM: 615290 and 618291]).16–20 Precisely, pathogenic variants in BICD2, an important golgin and cargo adaptor protein, cause a severe Golgi fragmentation phenotype in primary fibroblasts, increased microtubule stability leading to axonal growth and transport defects in cultured motor neurons, neuromuscular junction (NMJ) development, and locomotor impairment in mutant flies.21,22

Here, we report heterozygous variants in Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1 (GBF1 [MIM: 603698]) as being associated with an overlapping phenotype of HMN and CMT2. Our functional data demonstrate that GBF1 is present in neuronal tissues and cells relevant for the motor neuron (MN) pathology. Moreover, GBF1 variants, similar to BICD2 variants, lead to a markedly increased Golgi fragmentation phenotype, which was observed, invariably, in all the analyzed probands-derived fibroblasts.

We describe seven individuals carrying de novo or autosomal-dominantly inherited variants in GBF1 leading to a slowly progressive HMN/CMT2; the individuals are from four unrelated families (Figure 1A and Table 1). Informed consent from each studied subject was obtained by each institution (details are given in the Supplemental Material and Methods), and the entire study was conducted under the ethical approval of the University of Cologne (reference number: 13-022).

Proband 1 (family 1, Figure 1A) presented with an HMN. The onset was at 57 years of age and included slowly progressive asymmetric distal muscle weakness predominantly in lower extremities. Parents were reportedly clinically unaffected. Examination of the affected individual at 68 years of age revealed bilateral foot drop, steppage gait, and an asymmetric wasting of the anterior compartment muscles in distal legs (right > left) (Figure 2A). Ankle jerk reflexes were absent. Tibial motor nerve conduction studies revealed normal amplitudes (12 mV), whereas the distal peroneal compound muscle action potential (CMAP) amplitudes were severely reduced (0.1 mV on the right side and 0.9 mV on the left) but better preserved when recorded from the anterior tibial muscles (4.9 mV on the right and 12 mV on the left). The sural sensory nerve action potential (SNAP) was also normal (22 μV). Electromyography (EMG) showed spontaneous activity in the lower leg muscles only with chronic neurogenic changes in both the anterior tibial, medial gastrocnemius, and the dorsal interosseous muscle 1 (IOD1). Magnetic resonance imaging (MRI) of the lumbar spine revealed moderate spinal stenosis at the L3-L4 level but no evidence of compressive radiculopathies. MRI of the distal lower extremities revealed asymmetric hyperintensities of the anterior and posterior compartment of the right lower leg, suggesting partial fatty transformation of the affected muscles with much lesser involvement of the left lower leg muscles (Figure 2A).

As part of the NeurOmics consortium, an NGS-based gene panel excluded known mutations in genes implicated in lower motor neuron diseases. Subsequently, a trio-based whole-genome sequencing (trio-WGS) was carried out as previously described23 via Illumina's TruSeq PCR-free sample preparation kit and run on the Illumina HiSeqX sequencer. The raw sequences were aligned with the Burrows-Wheeler Alignment tool (BWA) (v.0.7.10), duplicates were marked and removed with Picard, and indels were aligned with GATKLite v.2.3.9.

Following the prioritization of variants by allele frequency, conservation, and predicted effect on protein function, a heterozygous de novo missense variant in exon 28 (GenBank: NM_001933.3; c.3410C>T [p.Ala1137Val]) was identified in GBF1 in the affected individual (Figure 1A and Table 1). The variant was absent from our in-house database composed of 3,550 sequenced samples (RD-Connect’s integrated platform for rare diseases) but present in the heterozygous state with a minor allele frequency of 2 in 282,866 (MAF = 7 × 10⁻⁵) in two individuals of African ancestry in gnomAD v.2.1.1. Although the presence of the identified variant in a population database such as gnomAD was controversial and challenging for variant interpretation, we decided to not exclude it and consider it as a plausible candidate because of (1) its de novo occurrence in an affected individual without a family history of the disease and (2) the rarity of this variant’s being plausible for a mild and adult late-onset phenotype with symptoms starting at 56 years of age in the individual, whereas the ages of the identified individuals in gnomAD were reported as being between 50–55 years.

Proband 2 (III.3), who is currently a 58-year-old female, from family 2, showed progressive weakness in distal extremity muscles. She was first evaluated for her disease at the age of 26 years upon the diagnosis of CMT2 in her aunt. In her family, there were in total five affected individuals from three consecutive generations (Figure 1A). On examination, she showed a steppage gait and walking on heels was not possible. She developed pes cavus and a hammertoe deformity, bilaterally. Nerve conduction studies (NCSs) revealed a clear axonal sensorimotor involvement, and EMG revealed chronic neurogenic changes (Table 1). Exome sequencing (ES) of the index individual was performed within the GENESIS (GEM.app) platform collaboration as previously described.24 ES identified a heterozygous variant in exon 33 of GBF1 (GenBank: NM_001933.3; c.4382G>T [p.Arg1461Gln]). The variant was absent from gnomAD and the GENESIS platform of 10,477 individuals, 1,396 of whom presented with CMT and 108 of whom presented with HMN. Sanger sequencing and segregation analyses in the available family members unveiled the same pathogenic variant in two other affected individuals, II.5 and IV.2 (Figure 1A). As expected from these data, the father (III.1) of the affected daughter IV.2 also carries the same variant; he was evaluated at the time of ES in the proband and only had mild complaints of calf muscle cramps in the absence of gait disturbance. Upon
Figure 1. Pedigrees of the Four Families Affected by GBF1 Variants, Chromatograms of These Variants, GBF1 Functional Domains, Identified Mutations, and Residues Conservation (A) Pedigrees of families 1–4 and Sanger chromatograms of the identified GBF1 variants. GBF1 variants are marked in rectangles. (B) Schematic representation of GBF1 (1,859 amino acids) showing the DCB, HUS, Sec7, and HDS1–3 domains. GBF1 mutations identified in this study as well as their location are marked in red. Protein sequence alignments of GBF1 orthologues are given for each mutated residue. All residues are highly conserved among species. DCB, dimerization and cyclophilin-binding; HUS, homology upstream of Sec7; HDS, homology downstream of Sec7.
Table 1. Clinical Features of Affected Probands Carrying GBF1 Variants

| Family | 1 | 2 | 3 | 4 |
|---|---|---|---|---|
| Proband | II.1 | III.3 | II.5 | III.1 | IV.2 | II.1 | II.1 |
| Sex/age (years) | male/73 | female/58 | male/died at 85 years | male/62 | female/39 | male/40 | male/54 |
| Ethnicity | German | Belgian | Belgian | Belgian | Belgian | Old Order Amish | German |
| Genotype | | | | | | | |
| Genomic (hg38) | 10:102370385C>T | 10:102377031G>A | 10:102370728G>A | 10:102368807G>A |
| Nucleotide | c.3410C>T | c.4382G>A | c.3525G>A | c.2945G>A |
| Protein change | p.Ala1137Val | p.Arg1461Gln | p.Trp1175Ter | p.Cys982Tyr |
| CADD | 25.6 | 23.3 | 39 | 31 |
| Inheritance | de novo | dominant | de novo | dominant |
| Phenotype | | | | |
| Age at onset | 57 years | 24 years | 52 years | 58 years | 33 years | childhood | 50 years |
| First symptoms | difficulty walking | difficulty walking | hand weakness, difficulty walking | calf cramps, foot deformities | frequent falls, ankle distortions | delayed motor milestones | difficulty walking |
| Clinical picture | distal HMN | CMT2 | CMT2 | CMT2 | CMT2 | CMT2 | distal HMN/SMA peroneal type |
| ILs—motor | no | no | mild hand muscle weakness | no | no | hand muscle weakness with bilateral thenar atrophy | slight weakness (score 4/5) in hand and finger muscles |
| LLs—motor | foot drop, impaired toe and heel walking R>L | impaired heel walking, pes cavus and hammer toe deformity | mild distal muscle weakness | no | no | foot drop, thin lower extremities, pes cavus deformity | foot drop, weak toe extensors, thin lower extremities, sharp shin sign, pes cavus deformity |
| ULs—sensory | normal | N/A | mild hypoesthesia | normal | reduced touch and vibration sense | normal | normal |
| LLs—sensory | normal | N/A | mildly reduced vibration sense | normal | reduced touch and vibration sense | numbness in feet, reduced proprioception | numbness in feet |
| ULs—reflexes | normal | N/A | absent biceps reflex | normal | normal | reduced biceps, triceps, and brachioradialis reflex | normal |
| LLs—reflexes | normal patella reflex, absent ankle jerk reflex | N/A | absent patella (right only) and ankle jerk reflex | normal | absent ankle jerk reflex | brisk patella reflex, absent ankle jerk reflex | brisk patella reflex, absent ankle jerk reflex |
| Bulbar/vocal | normal | normal | normal | normal | normal | mild dysarthria | normal |
| Overall maximal function | independent ambulation | independent ambulation | independent ambulation | independent ambulation | independent ambulation | independent ambulation | independent ambulation |

(Continued on next page)
| Family | 1 | 2 | 3 | 4 |
|--------|---|---|---|---|
| Proband | II.1 | III.3 | II.5 | III.1 | IV.2 | II.1 | II.1 |
| Walking aids | right foot orthosis | no | no | no | no | cane and orthotic inserts | no |
| EMG | spontaneous activity in LL with chronic neurogenic changes | chronic neurogenic changes | chronic neurogenic changes | chronic neurogenic changes | normal | chronic neurogenic changes | spontaneous activity in LL with chronic neurogenic changes |
| NCSs—motor | axonal involvement | axonal involvement | axonal involvement | axonal involvement | normal UL, mild axonal involvement in LL | axonal involvement | axonal involvement |
| NCSs—sensory | normal | axonal involvement | axonal involvement | axonal in UL, reduced velocity in LL (33 m/s) | normal | axonal involvement | normal |
| MRI muscle | fatty degeneration of lower extremity muscles, predominantly on the right | N/A | N/A | N/A | N/A | N/A | no |
| MRI spinal cord | degenerative changes at lumbar spine, moderate spinal canal stenosis at L3/4 | N/A | N/A | N/A | N/A | normal cervical spine | degenerative changes and moderate spinal stenosis at the thoracolumbar junction |

ULs, upper limbs; LLs, lower limbs; EMG, electromyography; NCSs, nerve conduction studies; MRI, magnetic resonance imaging.
examination, he exhibited foot deformities, and electrophysiological evaluation revealed an axonal neuropathy. This suggests a marked variability in clinical severity within this family.

Proband 3 (II.1) from family 3 (Figure 1A, Table 1) is a 40-year-old male and the only affected individual in a ten-sibling Amish family. Reportedly, he had a mild motor developmental delay thought to be due to a premature birth at 32 weeks. He walked at 18–24 months of age and was always seemingly clumsy as a child. He has had a slowly progressive phenotype. At the age of approximately 30 years, symmetric distal muscle weakness developed leading to thin lower extremities and a high steppage gait, compensatory hip flexion, foot drop, bilateral thenar atrophy, and a pes cavus deformity (Figure 2B). On examination, toe plantar flexion and dorsiflexion were absent (Medical Research Council [MRC] grade 0) and muscle strength in the hand and forearm muscles was reduced (wrist flexion/extension 4/5). He also exhibited mild dystrophy, distal sensory loss in lower extremities, decreased vibratory sense in the right foot (intact on left), and decreased proprioception of the great toes bilaterally, though it was intact in the ankles. Reflexes were 2/4 in biceps, triceps, and brachioradialis bilaterally. Deep tendon reflexes were 3/4 in quadriceps bilaterally and 0/4 in ankles. EMG showed chronic denervation on the right L3-L5 and CS-C6 segments, and tibial and peroneal motor nerve conduction studies showed absent compound muscle action potentials. MRI of the brain revealed minor deep white matter change consistent with periventricular leukomalacia from prematurity. We performed family ES of the proband, both unaffected parents, and two unaffected siblings as previously reported.25 Genomic DNA was sheared and prepared for exome capture with a custom reagent kit from Kapa Biosystems. Samples were captured with the NimbleGen VCRome 2.1 exome target design and sequenced with 75 bp paired-end sequencing on an Illumina HiSeq 2500 with v4 chemistry. Sequence reads were mapped and aligned to the human genome reference assembly via BWA-mem. Variants and genotypes were called with GATK’s HaplotypeCaller. Family-based analysis of the exome data identified a heterozygous variant (GenBank: NM_004193.3; c.3525G > A) in the proband.

We had already included GBF1 in our diagnostic neuromuscular disease panel, we readily identified a rare heterozygous variant in exon 23 of GBF1 (GenBank: NM_004193.3; c.2945G > A [p.Cys982Tyr]) in this individual in the routine diagnostic setting. In order to exclude other putative variants in all coding exons of the entire genome, we subsequently performed ES. Analysis of the ES data revealed no other putative variants that could explain the phenotype of this individual. The variant was not present in gnomAD nor in our in-house exome database. Interestingly, the variant was inherited from the putatively unaffected mother who had no neuromuscular complaints at the age of 73 years. However, as we were unable to perform any electrophysiological tests in the mother, a subclinical phenotype with a minor pathology could not be excluded.

GBF1 (6,403 bp) has a single large transcript of 6.4 kb (GenBank: NM_004193) that encodes 1,859 amino acids. It is relatively intolerant to missense variation, having a positive Z score of 2.41 (observed/expected ratio: 0.79, gnomAD v.2.1.1, accessed May 2020).

Of note, during routine splicing analyses (Human Splicing Finder 3.1), the variants c.3410C>T and c.4382G>A were predicted to potentially alter splicing by generating an exonic splicing silencer (ESS) or an exonic splicing enhancer (ESE), respectively. To test whether these two variants could alter GBF1 transcripts processing, we isolated RNA from cultured fibroblasts from the two probands and controls and performed RT-PCR by using primers flanking exons 27 (c.3410C>T) and 32 (c.4382G>A). In both cases, the generated PCR products corresponded only to full-length transcripts (346 bp for c.3410C>T and 387 bp for c.4382G>A) and excluded the possibility of splicing defects associated with the aforementioned GBF1 variants (Figure S1 and Supplemental Material and Methods).

GBF1 encodes a guanine-nucleotide exchange factor (GEF) of the Sec7 domain family that facilitates the GDP-to-GTP exchange for members of the ARF family of small GTPases. The activation of ARF proteins is crucial for the spatial-temporal regulation of membrane dynamics and cell organization.27,28 The main substrates of GBF1 are the evolutionary conserved class I ARF proteins (ARF1 [MIM: 103180], ARF3 [MIM: 103190], and ARF4 [MIM: 601177]).27 Residing at the Golgi membrane, the ARF1-GBF1 complex is well known for its important role in the
formation of the coatomer protein complex I (COPI) vesicles and the maintenance of the structure and function of the Golgi apparatus (GA). Nonetheless in the last years, new and unexpected roles and cellular localizations have been attributed to GBF1 (jointly or independently of ARF1); these include lipid droplet metabolism, mitochondrial function and positioning, Clathrin-independent endocytosis, and viral/pathogen infection (including corona viruses) and replication processes.

The domain architecture of GBF1 includes six partially characterized but highly conserved functional domains. The first two domains of the protein, namely the N-terminal DCB (dimerization and cyclophilin binding) and the HUS (homology upstream of Sec7) domains, regulate the oligomeric state of GBF1. The central Sec7 domain catalyzes the GDP/GTP exchange on ARF proteins and thereby their functional activation. The C-terminal region of GBF1 is crucial for GBF1 recruitment to the membrane. This region includes three HDS (homology downstream of the Sec7; HDS1–3) domains, of which HDS1 and HDS2 are necessary for GBF1 targeting to the GA because the deletion of these domains, alone or together, inhibits the targeting of the protein to Golgi membranes in vivo. Interestingly, the GBF1 pathogenic variants identified in this study occur in conserved residues that lie in the HDS1 and HDS2 domains of the protein exclusively (Figure 1B). The in silico combined annotation-dependent depletion (CADD) prediction scores were high for each variant (Table 1).

Several in vitro and in vivo studies have revealed important functions of GBF1 in development, physiology, and disease. Reduced GBF1 levels in cultured cells have been associated with loss of GA integrity, COPI dispersal, compromise of the intracellular traffic, and cell death. Nevertheless, it is important to highlight that tight regulation of GBF1 degradation is necessary for the physiological processes of post-mitotic GA re-assembly and cytokinesis completion. Moreover, GBF1 regulates mitochondrial dynamics because the blocking of GBF1 activity leads to defects in mitochondrial morphology, positioning, and migration.
Loss of function of arf-1 or gbf-1, the ARF1 and GBF1 orthologues in *C. elegans*, cause mitochondrial disorganization, hyperconnectivity, and reduced respiratory activity. Hence, gbf-1-depleted worms exhibit a severe reduction in muscle performance and developmental arrest. In vertebrates, the effect of Gbf1 depletion has been documented only in zebrafish. A zebrafish mutant line (*tsu3994*) carrying the loss-of-function Gbf1 mutation Leu1246Arg in the HSD2 domain of the protein exhibits vascular collapse and prominent intracerebral and trunk hemorrhage.

In humans, GBF1 is a ubiquitously abundant protein, however little information exists about its levels in neuronal tissues and specific neuronal populations. Thus, our first step was to confirm the presence of GBF1 in tissues and cells relevant for the HMN/CMT2 phenotype, namely in the spinal cord, brain, and muscle tissues and in MNs.

To analyze the specific localization of GBF1 in primary murine MNs, these were isolated from embryonic day 13.5 (E13.5)-old wild-type (WT) embryos, grown in culture for 7 days, and stained with a GBF1-specific antibody. For the selective visualization of MNs, cells were stained with antibodies against choline acetyltransferase (ChAT), which is routinely used as a marker of cholinergic MNs, and the neuronal-specific microtubule protein tau (Table S1 and Supplemental Material and Methods). Staining showed positive GBF1 signals throughout the whole MN and a particularly high abundance in the soma, and particularly in the GA region and the growth cone tip, where it is present in vesicle-like structures (Figures 3A–3C).

To shed some light onto the developmental requirements of GBF1, we analyzed protein levels during *in vitro* MN differentiation, i.e., days of *in vitro* culture (DIV) 4, 12, and 20, in WT embryonic MNs via immunoblot. Cells were supplemented with specific growth factors in order to promote neuronal differentiation *in vitro* (Supplemental Material and Methods). We observed a steady decrease in levels of GBF1 and increase of ARF1—a main GBF1-interacting partner—during the 20 days of neuronal differentiation (Figure 3D). Moreover, we confirmed GBF1 presence in total protein lysates from the brain, spinal cord, and muscle (gastrocnemius) isolated from WT mice at different postnatal stages (Figure S2). Both GBF1 and ARF1 decreased in neuronal tissues from postnatal day 10 (P10) to P28 (Figure S2).

Altogether, these results show that GBF1 is abundant in neuronal tissues and particularly in relevant MN pathology sites. Moreover, GBF1 levels during MN differentiation suggest that the protein plays an important yet unexplored role in neuronal development and maintenance.

All animal breeding and procedures were performed in accordance with the institutional animal care guidelines and the German animal welfare laws. They are approved under the reference numbers 84-02.04.2015.A378 and §4.18.002 of the State Agency for Nature, Environment, and Consumer Protection of the State North Rhine-Westphalia (LANUV NRW).

Given the important role of GBF1 in GA function and maintenance, and further considering that GBF1 depletion or inhibition has been linked with GA vesiculation and fragmentation, we focused our functional analyses ascertaining the effect of GBF1 mutations on GA organization by using primary fibroblast cells established from skin biopsies. We were able to establish fibroblast cell lines from all the probands belonging to the four unrelated families reported in this study. Immunoblot analyses of GBF1 did not reveal significant differences between GBF1 mutant cell lines in comparison to WT control lines, except for the cell line heterozygous for p.Trp1175Ter, where a WT full-length and a potentially truncated smaller protein product can be observed (Figure S3). Notwithstanding this, immunostainings with the GBF1 antibody and the cis Golgi marker GM130 (Table S1) revealed the expected enrichment of GBF1 in the GA and a more diffuse cytoplasmic signal of the protein in all fibroblast lines. Moreover, all mutant fibroblast lines exhibited significantly increased proportions of cells with a marked dispersal of both GBF1 and GM130 signals (from 8% in control cells up to 28% to 46% in probands’ fibroblasts), consistent with Golgi fragmentation (Figures 4A and 4B). Although the Golgi phenotype was slightly more pronounced in the fibroblast cell line derived from the proband with the p.Trp1175Ter alteration, possibly because of the truncating nature of the alteration, all probands’ fibroblasts exhibited marked GA phenotype and a general loss of the central Golgi ribbon stack. We postulate that Golgi fragmentation/vesiculation is the unifying pathogenic functional signature underlying *GBF1* heterozygous disease-associated variants.

In conclusion, our results support the association between *GBF1* pathogenic variants and the common phenotype of HMN and CMT2. *GBF1* not only expands the number of genetic loci associated with HMN/CMT2 but also corroborates Golgi fragmentation as a driver of length-dependent motor axonopathy.

Structural and functional alterations of the GA are currently recognized as an important pathological hallmark of various neurodegenerative diseases, including Parkinson, Alzheimer, Huntington, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), type-2 spinocerebellar ataxia (SCA2), SMAED2, and Creutzfeldt-Jakob diseases. In general, GA defects are considered as early or preclinical indicators of neuronal loss and range from extensive Golgi unstacking, vesiculation, and ribbon disconnection to generalized Golgi atrophy (loss of Golgi membrane material). Loss of Golgi integrity can have a detrimental effect in cargo transport velocity, mitosis completion, autophagy regulation, cell polarity, and migration. Most precisely, in neurons, the GA is crucial for dendrite formation and growth, axonal polarity, and cell migration during brain development. Interestingly, *de novo* missense mutations affecting the GDP/GTP-binding site of ARF1 were found in three unrelated individuals and associated with periventricular...
**Figure 3. Localization and GBF1 Abundance in Relevant Motor Neuropathology Tissues**

(A) GBF1 localization in primary MNs. Representative image of MNs isolated from WT E13.5 embryos cultured 7 days in vitro (DIV7). Immunostaining shows high abundance of GBF1 in the cell body, axon, and growth cone. Lower panels include a low-exposure image of GBF1 (marked with an arrow) that depicts protein enrichment in the GA and ChAT-positive immunoreactivity. Depicted stainings are GBF1 (white), ChAT (magenta), Tau (green), and phalloidin (blue). Scale bar represents 20 μm. Inset scale bar represents 10 μm.

(B) GBF1 fluorescent intensity is depicted with rainbow intensities to highlight MN zones of higher protein accumulation. Scale bar represents 20 μm.

(C) GBF1 is abundantly present in the MN growth cone. Depicted stainings are GBF1 (white), ChAT (magenta), Tau (green), and Phalloidin (blue). Scale bar represents 20 μm.

(D) GBF1 expression decreases over time in differentiating primary MNs. MNs isolated from WT E13.5 embryos were cultured during 20 days in the presence of growth factors. Total protein lysates were collected at the indicated time points. Immunoblots were probed against GBF1 and ACTB as the normalization housekeeper. Graphs represent quantification of relative expression of GBF1. Bars show the mean ± SEM from three independent samples. Asterisk denotes statistical significance (**p = 0.001, two-tailed Student's t test) between the different time points compared to DIV4.
Figure 4. Pathogenic GBF1 Variants Cause Golgi Fragmentation

(A) Representative images of fibroblast cells derived from control or affected individuals. Immunostainings show GBF1 presence in the whole cell and enrichment in the GA region. Depicted stainings are GBF1 (green), GM130 (magenta), and nucleus (DAPI, blue). Scale bar represents 25 μm. Scale bar of magnification insets represents 25 μm. The dispersion of the GM130 signal was used to establish three categories of GA structure: condensed or no fragmentation, intermediate fragmentation, and diffuse or extensive fragmentation. Extensive fragmentation of the GA can be appreciated in magnified insets of representative images from affected fibroblast compared to control.

(B) GA structures were quantified in more than 300 cells representing at least three independent double-blinded experiments. Graph represents GA fragmentation quantification. Bars show mean ± SD. Asterisks denote statistical significance (**p = 0.01 and ****p = 0.0001, one-way ANOVA and Dunnett’s correction for multiple comparisons). “NS” denotes no significance.

The American Journal of Human Genetics 107, 763–777, October 1, 2020
nodular heterotopia-8 (PVNH8, [MIM: 618185]), a neurologic disorder characterized by abnormal neuronal migration during brain development and concomitant delay in psychomotor development. Similarly, bi-allelic variants in a second ARF1 activator, ADP-ribosylation factor guanine nucleotide exchange factor 2 (ARFGEF2 [MIM: 605371]), were associated with proliferation and migration defects of cortical neurons, causing a severe malformation of the cerebral cortex known as periventricular heterotopia with microcephaly (ARPHM [MIM: 608097]). Furthermore, individuals with severe SMALED2, as well as the Bicd2<sup>−/−</sup> mouse model, also exhibit profound cerebellar hypoplasia and cortical migration defects. We postulate that GBF1 pathogenic variants, similar to ARF1, ARFGEF2, and BICD2 variants, could underlie migration defects in MNs, considering not only the abundance of the protein in the spinal cord but also the early developmental requirements thereof. As for BICD2-opathies, we previously described phenotypic extremes in individuals with the same BICD2 pathogenic variants with very different levels of phenotypic severity, including a proband with an early onset severe phenotype and an asymptomatic parent. Similarly, we observed phenotypic variability in our GBF1 family pedigrees, although it remains unclear whether the asymptomatic mutation carriers in this study exhibit a discrete subclinical phenotype suggesting variable expression or a complete absence of disease consistent with incomplete penetrance. Because of the late onset and mild course of the HMN/CMT2 phenotypes described here, a well-founded conclusion about the expressivity and penetrance of the disease could not be reached at this point. Another explanation regarding protective genetic modifiers abrogating the disease-onset or progression remains possible.

The molecular mechanism behind GBF1 mutations and Golgi fragmentation remains to be elucidated. Nevertheless, since GBF1 is a central player in molecular pathways that are necessary for GA maintenance, structure, and function, we hypothesize that pathogenic GBF1 mutations could drive GA pathology by compromising either the Golgi transport machinery or the microtubule control of Golgi structure and positioning. Indeed, traffic impairment between the Golgi, the endoplasmic reticulum (ER), and the ERGIC (ER-Golgi intermediate compartment), i.e., defects in COPI and COPII vesicle-coat complexes, can lead to severe GA structural defects. In this respect, it is important to emphasize that the activation of ARF1 by GBF1 is crucial for the assembly of the COPI vesicle-coat complex at the Golgi and ERGIC membranes and that the inactivation or depletion of GBF1 causes COPI dissociation from membranes with concomitant GA fragmentation. On the other hand, the microtubule (MT) network is essential not only for the structural maintenance and positioning of the GA, but also for the anterograde and retrograde movement of cargo at the cis and trans Golgi networks. In fact, MT depolymerization causes dispersion of the GA ribbon. During neurodegeneration, fragmented Golgi structures appeared dispersed throughout the cell, further implying a disconnection of the GA and the cytoskeleton. Most interestingly, the GA, other than the centrosome, is a center for MT nucleation and is of particular relevance for polarized cells, such as the MN. Indeed, Golgi outposts of a centrosomal MT polymerization shape dendrite morphology and could explain the susceptibility of MNs and other neuronal populations to Golgi defects. Another possibility that cannot be ruled out is that Golgi fragmentation is a secondary phenotype derived from the impairment of another cellular process or organelle. Mitochondrial defects have been proposed as a trigger of GA fragmentation and the activation of the Golgi stress response, and GBF1 inhibition impairs dynein and MIRO (1 and 2)-dependent retrograde mitochondrial transport along MTs towards the microtubule organizing center. Moreover, mitochondrial defects in Mitofusin 2 (Mfn2 [MIM: 608507]) and ganglioside-induced differentiation-associated-protein 1 (Gdap1 [MIM: 606598]) are associated with CMT2. GBF1 interactions with proteins of the secretory pathways, molecular motors, and mitochondrial regulators hold the key to understanding the molecular determinants of Golgi fragmentation and represent promising HMN-causative gene candidates that remain to be discovered.

Data and Code Availability

The variants were deposited in Clinvar and are accessible via the accession codes VCV000972907, VCV000973612, VCV000972904, and VCV000975152. NGS dataset of family 1 is available in the European Genome-phenome Archive (EGA) under following accession codes: EGAN00001366899, EGAN00001366900, EGAN00001366901. Sequence datasets of other families might be available from the corresponding author upon request. Please contact M.K. and B.W. for further information.

Supplemental Data

Supplemental Data can be found online at https://doi.org/10.1016/j.ajhg.2020.08.018.

Acknowledgments

We would like to thank the family members described herein for participating in this study. We thank all our clinical collaborators for the support at clinical follow-up, diagnostics, and the genetic analysis. We furthermore thank the Regional Computing Center of the University of Cologne (RZZK) for providing computing time and storage on the CHEOPS high performance computing cluster. This work was supported by the Deutsche Forschungsgemeinschaft (Wi945/19-1 and RTG 1960 to B.W.), NRW Innovation Award (B.W.), the European Community’s Seventh Framework Programme (FP7/2007–2013) under grant 2012-305121 (NEUROMICS) (B.W. and J.B.), the Center for Molecular Medicine Cologne (C18 to B.W. and M.K.), the Association Belge contre les Maladies...
Neuromusculaire (ABMM)—Aide à la Recherche ASBL (2017-2018/05) (D.B. and J.B.). J.B. is supported by a Senior Clinical Researcher mandate of the Research Fund-Flanders (FWO) under grant 1805016N. We are thankful for access to the GENESIS analysis platform and Varbank analysis platform.

Declaration of Interests

C.G.-J. is a full-time employee of the Regeneron Genetics Center and receives stock options as part of compensation. All other authors declare no competing interests

Received: May 29, 2020
Accepted: August 19, 2020
Published: September 15, 2020

Web Resources

Combined Annotation Dependent Depletion (CADD), https://cadd.gs.washington.edu
Ensembl Genome Browser, http://www.ensembl.org/index.html
European Genome-Phenome Archive, https://ega-archive.org
Inherited Neuropathy Variant Browser, http://hig.med.miami.edu/code/http/cmt/public_html/index.html
Multiple sequence alignment CLUSTALW2, https://www.ebi.ac.uk/Tools/msa/clustalw2/
Muscle Gene Table, http://musclegenetable.fr
Neuromics Consortium, https://rd-neuromics.eu/
Online Mendelian Inheritance in an (OMIM), https://www.omim.org/
RD Connect Database, https://platform.rd-connect.eu/
The Genome Aggregation Database, https://gnomad.broadinstitute.org/
Varbank Variant Analysis Platform, https://varbank.ccg.uni-koeln.de/varbank2/

References

1. Landrieu, P., Baets, J., and De Jonghe, P. (2013). Hereditary motor-sensory, motor, and sensory neuropathies in childhood. Handb. Clin. Neurol. 113, 1413–1432.
2. Klein, C.J., Duan, X., and Shy, M.E. (2013). Inherited neuropathies: clinical overview and update. Muscle Nerve 48, 604–622.
3. Harding, A.E., and Thomas, P.K. (1980). Genetic aspects of hereditary motor and sensory neuropathy (types I and II). J. Med. Genet. 17, 329–336.
4. Harding, A.E. (2005). Inherited Neuronal Atrophy and Degeneration Predominantly of Lower Motor Neurons* A2 - Dyck, Peter J. In Peripheral Neuropathy, Fourth Edition, P.K. Thomas, ed. (Philadelphia: W.B. Saunders), pp. 1603–1621.
5. Bansagi, B., Grifin, H., Whittaker, R.G., Antoniadi, T., Evangelista, T., Miller, J., Greenslade, M., Forester, N., Duff, J., Bradshaw, A., et al. (2017). Genetic heterogeneity of motor neuropathies. Neurology 88, 1226–1234.
6. Gonzaga-Jauregui, C., Harel, T., Gambin, T., Kousi, M., Grifin, I.B., Francescatto, L., Ozes, B., Karaca, E., Jhangiani, S.N., Bainbridge, M.N., et al.; Baylor-Hopkins Center for Mendelian Genomics (2015). Exome Sequence Analysis Suggests that Genetic Burden Contributes to Phenotypic Variability and Complex Neuropathy. Cell Rep. 12, 1169–1183.
7. Irobi, J., Van Impe, K., Seeman, P., Jordanova, A., Dierick, I., Verpoorten, N., Michalik, A., De Vriendt, E., Jacobs, A., Van Gerwen, V., et al. (2004). Hot-spot residue in small heat-shock protein 22 causes distal motor neuropathy. Nat. Genet. 36, 597–601.
8. Evgrafov, O.V., Mersiyanova, I., Irobi, J., Van Den Bosch, L., Dierick, I., Leung, C.L., Schagina, O., Verpoorten, N., Van Impe, K., Fedotov, V., et al. (2004). Mutant small heat-shock protein 27 causes axonal Charcot-Marie-Tooth disease and distal hereditary motor neuropathy. Nat. Genet. 36, 602–606.
9. Ackerley, S., James, P.A., Kalli, A., French, S., Davies, K.E., and Talbot, K. (2006). A mutation in the small heat-shock protein HSPB1 leading to distal hereditary motor neuropathy disrupts neurofilament assembly and the axonal transport of specific cellular cargoes. Hum. Mol. Genet. 15, 347–354.
10. Irobi, J., Almeida-Souza, L., Asselbergh, B., De Winter, V., Goethals, S., Dierick, I., Krishnan, J., Timmermans, J.P., Robberecht, W., De Jonghe, P., et al. (2010). Mutant HSPB8 causes motor neuron-specific neurite degeneration. Hum. Mol. Genet. 19, 3254–3265.
11. Puls, I., Jonnakuty, C., LaMonte, B.H., Holzbaur, E.L., Tokito, M., Mann, E., Fletter, M.K., Bidus, K., Drayna, D., Oh, S.J., et al. (2003). Mutant dynactin in motor neuron disease. Nat. Genet. 33, 455–456.
12. Levy, J.R., Sumner, C.J., Caviston, J.P., Tokito, M.K., Rangarajan, S., Ligon, A., Wallace, K.E., LaMonte, B.H., Harmison, G.G., Puls, I., et al. (2006). A motor neuron disease-associated mutation in p50Glued perturbs dynactin function and induces protein aggregation. J. Cell Biol. 172, 733–745.
13. Calvo, J., Funalot, B., Ouvrier, R.A., Lazaro, L., Toutain, A., De Mas, P., Bouché, P., Gilbert-Dussardier, B., Arne-Bes, M.C., Carriere, J.P., et al. (2009). Genotype-phenotype correlations in Charcot-Marie-Tooth disease type 2 caused by mitofusin 2 mutations. Arch. Neurol. 66, 1511–1516.
14. Claey, K.G., Zichner, S., Kennerson, M., Berzjano, J., Garcia, A., Verhoeven, K., Storey, E., Merory, J.R., Bienfait, H.M., Lamens, M., et al. (2009). Phenotypic spectrum of dynamin 2 mutations in Charcot-Marie-Tooth neuropathy. Brain 132, 1741–1752.
15. Charlesworth, G., Balint, B., Mencacci, N.E., Carr, L., Wood, N.W., and Bhatia, K.P. (2016). SLC25A46 mutations underlie progressive myoclonic ataxia with optic atrophy and neuropathy. Mov. Disord. 31, 1249–1251.
16. Martinez-Carrera, L.A., and Wirth, B. (2015). Dominant spinal muscular atrophy is caused by mutations in BICD2, an important golgin protein. Front. Neurosci. 9, 401.
17. Neveling, K., Martinez-Carrera, L.A., Höller, I., Heister, A., Verrips, A., Hossei-Harkooie, S.M., Gilissen, C., Vermeir, S., Pennings, M., Meijer, R., et al. (2013). Mutations in BICD2, which encodes a golgin and important motor adaptor, cause congenital autosomal-dominant spinal muscular atrophy. Am. J. Hum. Genet. 92, 946–954.
18. Peeters, K., Litvinenko, I., Asselbergh, B., Almeida-Souza, L., Chamova, T., Geuens, T., Ydens, E., Zimoni, M., Irobi, J., De Vriendt, E., et al. (2013). Molecular defects in the motor adaptor BICD2 cause proximal spinal muscular atrophy with autosomal-dominant inheritance. Am. J. Hum. Genet. 92, 955–964.
19. Oates, E.C., Rossor, A.M., Hafezprast, M., Gonzalez, M., Speziani, F., MacArthur, D.G., Lek, M., Cottenie, E., Soto, M., Foley, A.R., et al.; UK10K (2013). Mutations in BICD2 cause
dominant congenital spinal muscular atrophy and hereditary spastic paraplegia. Am. J. Hum. Genet. 92, 965–973.

20. Storbeck, M., Horsberg Eriksen, B., Unger, A., Höfler, I., Aukrust, I., Martinez-Carrera, L.A., Linke, W.A., Ferbert, A., Heller, R., Vorgerd, M., et al. (2017). Phenotypic extremes of BICD2-opathies: from lethal, congenital muscular atrophy with arthrogryposis to asymptomatic with subclinical features. Eur. J. Hum. Genet. 25, 1040–1048.

21. Martinez Carrera, L.A., Gabriel, E., Donohoe, C.D., Höfler, I., Mariappan, A., Storbeck, M., Uhlbrova, M., Gopalakrishnan, J., and Wirth, B. (2018). Novel insights into SMALED2: BICD2 mutations increase microtubule stability and cause defects in axonal and NMJ development. Hum. Mol. Genet. 27, 1772–1784.

22. Hoogenraad, C.C., and Akhamanova, A. (2016). Bicaudal D Family of Motor Adaptors: Linking Dyneme Motility to Cargo Binding. Trends Cell Biol. 26, 327–340.

23. Karakaya, M., Storbeck, M., Strathmann, E.A., Delle Vedove, A., Höfler, I., Altmueller, J., Naghiyeva, L., Schmitz-Steinkrüger, L., Vezyroglou, K., Motameny, S., et al. (2018). Targeted sequencing with expanded gene profile enables high diagnostic yield in non-5q-spasial muscular atrophies. Hum. Mutat. 39, 1284–1298.

24. Gonzalez, M., Falk, M.J., Gai, X., Postrel, R., Schüle, R., and Zuchner, S. (2015). Innovative genomic collaboration using the GENESIS (GEM.app) platform. Hum. Mutat. 36, 950–956.

25. Strauss, K.A., Gonzaga-Jauregui, C., Brigatti, K.W., Williams, K.B., King, A.K., Van Hout, C., Robinson, D.L., Young, M., Praveen, K., Heaps, A.D., et al. (2018). Genomic diagnostics within a medically underserved population: efficacy and implications. Genet. Med. 20, 31–41.

26. Sobreira, N., Schiettecatte, E., Valle, D., and Hamosh, A. (2015). GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. Hum. Mutat. 36, 928–930.

27. Donaldson, J.G., and Jackson, C.L. (2011). ARF family G proteins and their regulators: roles in membrane transport, development and disease. Nat. Rev. Mol. Cell Biol. 12, 362–375.

28. Donaldson, J.G., and Klausner, R.D. (1994). ARF: a key regulatory switch in membrane traffic and organelle structure. Curr. Opin. Cell Biol. 6, 527–532.

29. García-Mata, R., Szul, T., Alvarez, C., and Sztul, E. (2003). ADP-ribosylation factor/COPD-dependent events at the endoplasmic reticulum-Golgi interface are regulated by the guanine nucleotide exchange factor GBF1. Mol. Biol. Cell 14, 2250–2261.

30. Szul, T., Grabski, R., Lyons, S., Morohashi, Y., Shestopal, S., Lowe, M., and Sztul, E. (2007). Dissecting the role of the ARF guanine nucleotide exchange factor GBF1 in Golgi biogenesis and protein trafficking. J. Cell Sci. 120, 3929–3940.

31. Kawamoto, K., Yoshida, Y., Tamaki, H., Torii, S., Shinotsuka, C., Yamashina, S., and Nakayama, K. (2002). GBF1, a guanine nucleotide exchange factor for ARF-ribosylation factors, is localized to the cis-Golgi and involved in membrane association of the COP1 coat. Traffic 3, 483–495.

32. Manolea, F., Claude, A., Chun, J., Rosas, J., and Melançon, P. (2008). Distinct functions for ARF guanine nucleotide exchange factors at the Golgi complex: GBF1 and BICs are required for assembly and maintenance of the Golgi stack and trans-Golgi network, respectively. Mol. Biol. Cell 19, 523–535.

33. Yadav, S., Puthenveedu, M.A., and Linstedt, A.D. (2012). Golgin160 recruits the dynein motor to position the Golgi apparatus. Dev. Cell 23, 153–165.

34. Bouvet, S., Golinelli-Cohen, M.P., Contremoulins, V., and Jackson, C.L. (2013). Targeting of the Arf-GEF GBF1 to lipid droplets and Golgi membranes. J. Cell Sci. 126, 4794–4805.

35. Ackema, K.B., Hench, J., Böckler, S., Wang, S.C., Sauder, U., Mengertaler, H., Westermann, B, Far, D., Frank, S., and Spang, A. (2014). The small GTPase Arf1 modulates mitochondrial morphology and function. EMBO J. 33, 2659–2675.

36. Walch, L., Pellier, E., Leng, W., Lakisic, G., Gauvert, A., Contremoulins, V., Verbavatz, J.M., and Jackson, C.L. (2018). GBF1 and Arf1 interact with Miro and regulate mitochondrial positioning within cells. Sci. Rep. 8, 17121.

37. Gupta, G.D., Swetha, M.G., Kumar, S., Lakshminarayan, R., Dey, G., and Mayor, S. (2009). Analysis of endocytic pathways in Drosophila cells reveals a conserved role for GBF1 in internalization via GEECs. PLoS ONE 4, e6768.

38. Witkos, T.M., Chan, W.L., Joensuu, M., Rhiel, M., Pallister, E., Thomas-Oates, J., Mood, A.P., Mironov, A.A., Biot, C., Guerdel, Y., et al. (2019). GORAB scaffolds COPI at the trans-Golgi for efficient enzyme recycling and correct protein glycosylation. Nat. Commun. 10, 127.

39. Ferlin, J., Farhat, R., Belouzard, S., Cocquerel, L., Bertin, A., Hober, D., Dubuisson, J., and Rouillé, Y. (2018). Investigation of the role of GBF1 in the replication of positive-sense single-stranded RNA viruses. J. Gen. Virol. 99, 1086–1096.

40. Belov, G.A., Kovtunovych, G., Jackson, C.L., and Ehrenfeld, E. (2010). Poliovirus replication requires the N-terminus but not the catalytic Sec7 domain of ArfGEP1 GBF1. Cell. Microbiol. 12, 1463–1479.

41. Goueslain, L., Alsaleh, K., Holrellou, P., Roingeard, P., Descamps, V., Duverlie, G., Ciczora, Y., Wychowski, C., Dubuisson, J., and Rouillé, Y. (2010). Identification of GBF1 as a cellular factor required for hepatitis C virus RNA replication. J. Virol. 84, 773–787.

42. Iglesias, N.G., Mondotte, J.A., Byk, L.A., De Maio, F.A., Samsa, M.M., Alvarez, C., and Gamarnik, A.V. (2015). Dengue Virus Uses a Non-Canonical Function of the Host GBF1-Arf-COPI System for Capsid Protein Accumulation on Lipid Droplets. Traffic 16, 962–977.

43. de Wilde, A.H., Wannee, K.F., Scholte, F.E., Goeman, J.J., ten Diijke, P., Snijder, E.J., Kikkert, M., and van Hemert, M.J. (2015). A Kinome-Wide Small Interfering RNA Screen Identifies Proviral and Antiviral Host Factors in Severe Acute Respiratory Syndrome Coronavirus Replication, Including Double-Stranded RNA-Activated Protein Kinase and Early Secretory Protein Pathways. J. Virol. 89, 8318–8333.

44. Ramaen, O., Joubert, A., Simister, P., Belgareh-Touzé, N., Oliwares-Sanchez, M.C., Zeeh, J.C., Chantalat, S., Golinelli-Cohen, M.P., Jackson, C.L., Biou, V., and Cherfils, J. (2007). Interactions between conserved domains within homodimers in the BIG1, BIG2, and GBF1 Arf guanine nucleotide exchange factors. J. Biol. Chem. 282, 28834–28842.

45. Bhatt, J.M., Viktorrova, E.G., Busby, T., Wyrozsma, P., Newman, L.E., Lin, H., Lee, E., Wright, J., Belov, G.A., Kahn, R.A., and Sztul, E. (2016). Oligomerization of the Sec7 domain Arf guanine nucleotide exchange factor GBF1 is dispensable for Golgi localization and function but regulates degradation. Am. J. Physiol. Cell Physiol. 310, C456–C469.
76. Machamer, C.E. (2015). The Golgi complex in stress and death. Front. Neurosci. 9, 421.

77. Nakagomi, S., Barsoum, M.J., Bossy-Wetzel, E., Sütterlin, C., Malhotra, V., and Lipton, S.A. (2008). A Golgi fragmentation pathway in neurodegeneration. Neurobiol. Dis. 29, 221–231.

78. Cassereau, J., Chevrollier, A., Gueguen, N., Desquiret, V., Verny, C., Nicolas, G., Dubas, F., Amati-Bonneau, P., Reynier, P., Bonneau, D., and Procaccio, V. (2011). Mitochondrial dysfunction and pathophysiology of Charcot-Marie-Tooth disease involving GDAP1 mutations. Exp. Neurol. 227, 31–41.

79. Stuppia, G., Rizzo, F., Riboldi, G., Del Bo, R., Nizzardo, M., Simone, C., Comi, G.P., Bresolin, N., and Corti, S. (2015). MFN2-related neuropathies: Clinical features, molecular pathogenesis and therapeutic perspectives. J. Neurol. Sci. 356, 7–18.